Belantamab Mafodotin Monotherapy for Multiply‐Relapsed Myeloma: A Retrospective Study From the United Kingdom and the Republic of Ireland

ABSTRACT Introduction Belantamab mafodotin (belamaf) was the first BCMA‐targeting immunotherapy licensed in myeloma and was available as monotherapy for a fifth or greater line of treatment. Outcomes for patients in the United Kingdom and the Republic of Ireland potentially differ from those of othe...

Descrición completa

Detalles Bibliográficos

Principais autores:	Edmund C. R. Watson, Faouzi Djebbari, Fotios Panitsas, Grant Vallance, Samir Asher, Malahat Saeed, Mairi Walker, Matthew Powell, Alexandros Rampotas, Heather Leary, Akhil Khera, Angharad Atkinson, Ni Ni Aung, Gillian Brearton, Joseph Froggatt, Ezzat El Hassadi, Ellen Gokkel, Sarah Lawless, Beena Salhan, Salim Shafeek, Anand Lokare, Carol Stirling, Udo Oppermann, Richard Soutar, Rakesh Popat, Charalampia Kyriakou, Karthik Ramasamy
Formato:	Artigo
Idioma:	Inglês
Publicado:	Wiley 2025-06-01
Series:	eJHaem
Assuntos:	BCMA belantamab mafodotin immunotherapy keratopathy real‐world
Acceso en liña:	https://doi.org/10.1002/jha2.70039
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!